Edition:
India

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

636.00INR
24 Apr 2018
Change (% chg)

Rs-6.55 (-1.02%)
Prev Close
Rs642.55
Open
Rs646.95
Day's High
Rs653.00
Day's Low
Rs632.70
Volume
2,857,131
Avg. Vol
2,392,932
52-wk High
Rs809.45
52-wk Low
Rs503.05

Chart for

About

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system,... (more)

Overall

Beta: 0.84
Market Cap(Mil.): Rs437,068.31
Shares Outstanding(Mil.): 585.88
Dividend: 1.25
Yield (%): 0.52

Financials

  ARBN.NS Industry Sector
P/E (TTM): 19.51 30.95 32.74
EPS (TTM): 38.23 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Aurobindo Pharma Says U.S. FDA Issued Form 483 With 9 Observations for Co's Unit

* AUROBINDO PHARMA LTD CLARIFIES ON NEWS ITEM ON CO'S UNIT 4 GETTING 9 OBSERVATIONS AFTER U.S. FDA INSPECTION

05 Mar 2018

BUZZ-India's Aurobindo Pharma falls; USFDA cites quality issues at unit - report

** Drugmaker Aurobindo Pharma Ltd falls as much as 5.5 pct to 590 rupees, its lowest since Feb 23

05 Mar 2018

MEDIA-India's Aurobindo Pharma eyes European business of Apotex - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

21 Feb 2018

BRIEF-Aurobindo Pharma Says Approved Dividend Of 1 Rupee Per Share

* SAYS APPROVED SECOND INTERIM DIVIDEND OF 1 RUPEE PER SHARE Source text for Eikon: Further company coverage:

07 Feb 2018

Aurobindo Pharma Q3 profit up about 3 pct, misses estimates

Feb 7 Aurobindo Pharma Ltd, India's third largest drugmaker by revenue, posted an about 3 percent rise in quarterly profit on Wednesday, but missed analysts' estimates.

07 Feb 2018

BRIEF-India's Aurobindo Pharma Dec-Qtr Consol Net Profit Rises About 3 Pct

* DEC QUARTER CONSOL NET PROFIT 5.95 BILLION RUPEES VERSUS 5.79 BILLION RUPEES LAST YEAR

07 Feb 2018

BRIEF-Aurobindo Pharma Gets U.S. FDA Approval For Fondaparinux Sodium Injection

* SAYS GETS U.S. FDA APPROVAL FOR FONDAPARINUX SODIUM INJECTION Source text - http://bit.ly/2pK1kNR Further company coverage:

27 Dec 2017

BRIEF-Aurobindo Pharma Says News On Co Being Frontrunner to Buy Orchid Pharma "Factually Incorrect"

* AUROBINDO PHARMA CLARIFIES ON NEWS ITEM, "AUROBINDO, DR REDDY'S LABORATORIES FRONTRUNNERS TO BUY OUT BANKRUPT ORCHID PHARMA"

18 Dec 2017

BUZZ-India's Aurobindo Pharma down after Q2 results

** Aurobindo Pharma Ltd falls as much as 3.5 pct to 762.20 rupees

10 Nov 2017

Aurobindo Pharma second-quarter profit rises 29 percent, beats estimates

India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

09 Nov 2017

Earnings vs. Estimates